Qiang Zhou
Directeur/Membre du Conseil chez Taizhou EOC Pharma Co., Ltd.
Profil
Qiang Zhou is an Independent Director at Taizhou EOC Pharma Co., Ltd.
He has a graduate degree from the University of Pittsburgh, a doctorate degree from Stony Brook University, and an undergraduate degree from Tsinghua University.
Postes actifs de Qiang Zhou
| Sociétés | Poste | Début |
|---|---|---|
Taizhou EOC Pharma Co., Ltd.
 Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Directeur/Membre du Conseil | 15/04/2020 |
Formation de Qiang Zhou
| Tsinghua University | Undergraduate Degree |
| University of Pittsburgh | Graduate Degree |
| Stony Brook University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | Health Technology |